Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522
Copyright © 2021. Published by Elsevier Ltd..
OBJECTIVES: To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC).
MATERIAL AND METHODS: Clinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Significant predictors of OS, FFLR, and FFDM were obtained using univariate analysis on the training dataset. Nomograms were built using multivariate analysis with four a priori variables (age, gender, T-stage, and N-stage) and significant predictors from the univariate analyses. These nomograms were internally and externally validated using c-statistics (c) on the training and validation datasets, respectively.
RESULTS: The OS nomogram included age, gender, T stage, N stage, and number of cisplatin cycles. The FFLR nomogram included age, gender, T-stage, N-stage, and time-equivalent biologically effective dose. The FFDM nomogram included age, gender, N-stage, and number of cisplatin cycles. Internal validation of the OS nomogram, FFLR nomogram, and FFDM nomogram yielded c = 0.66, c = 0.66 and c = 0.73, respectively. External validation of these nomograms yielded c = 0.59, c = 0.70, and c = 0.73, respectively. Using nomogram score cutoffs, three risk groups were separated for each outcome.
CONCLUSIONS: We have developed and validated easy-to-use nomograms for LSCC outcomes using prospective cooperative group trial data.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
|---|---|
| Enthalten in: |
Oral oncology - 116(2021) vom: 02. Mai, Seite 105241 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Awan, Musaddiq J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemoradiation |
|---|
| Anmerkungen: |
Date Completed 31.01.2022 Date Revised 03.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.oraloncology.2021.105241 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321984757 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321984757 | ||
| 003 | DE-627 | ||
| 005 | 20231225181051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2021.105241 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM321984757 | ||
| 035 | |a (NLM)33640577 | ||
| 035 | |a (PII)S1368-8375(21)00064-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Awan, Musaddiq J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2022 | ||
| 500 | |a Date Revised 03.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Ltd. | ||
| 520 | |a OBJECTIVES: To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC) | ||
| 520 | |a MATERIAL AND METHODS: Clinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Significant predictors of OS, FFLR, and FFDM were obtained using univariate analysis on the training dataset. Nomograms were built using multivariate analysis with four a priori variables (age, gender, T-stage, and N-stage) and significant predictors from the univariate analyses. These nomograms were internally and externally validated using c-statistics (c) on the training and validation datasets, respectively | ||
| 520 | |a RESULTS: The OS nomogram included age, gender, T stage, N stage, and number of cisplatin cycles. The FFLR nomogram included age, gender, T-stage, N-stage, and time-equivalent biologically effective dose. The FFDM nomogram included age, gender, N-stage, and number of cisplatin cycles. Internal validation of the OS nomogram, FFLR nomogram, and FFDM nomogram yielded c = 0.66, c = 0.66 and c = 0.73, respectively. External validation of these nomograms yielded c = 0.59, c = 0.70, and c = 0.73, respectively. Using nomogram score cutoffs, three risk groups were separated for each outcome | ||
| 520 | |a CONCLUSIONS: We have developed and validated easy-to-use nomograms for LSCC outcomes using prospective cooperative group trial data | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Chemoradiation | |
| 650 | 4 | |a Larynx Cancer | |
| 650 | 4 | |a Nomograms | |
| 650 | 4 | |a Prognostic Factors | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Gittleman, Haley |e verfasserin |4 aut | |
| 700 | 1 | |a Barnholtz-Sloan, Jill |e verfasserin |4 aut | |
| 700 | 1 | |a Machtay, Mitchell |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen-Tan, Phuc Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenthal, David I |e verfasserin |4 aut | |
| 700 | 1 | |a Schultz, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Huth, Bradley J |e verfasserin |4 aut | |
| 700 | 1 | |a Thorstad, Wade L |e verfasserin |4 aut | |
| 700 | 1 | |a Frank, Steven J |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Harold |e verfasserin |4 aut | |
| 700 | 1 | |a Foote, Robert L |e verfasserin |4 aut | |
| 700 | 1 | |a Lango, Miriam N |e verfasserin |4 aut | |
| 700 | 1 | |a Shenouda, George |e verfasserin |4 aut | |
| 700 | 1 | |a Suntharalingam, Mohan |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Quynh-Thu |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Min |e verfasserin |4 aut | |
| 700 | 0 | |a NRG Oncology Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral oncology |d 1998 |g 116(2021) vom: 02. Mai, Seite 105241 |w (DE-627)NLM091475074 |x 1879-0593 |7 nnns |
| 773 | 1 | 8 | |g volume:116 |g year:2021 |g day:02 |g month:05 |g pages:105241 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.oraloncology.2021.105241 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 116 |j 2021 |b 02 |c 05 |h 105241 | ||